AVENTIS PHARMACEUTICALS PRODUCTS INC.
Patent Owner
Stats
- 11 US PATENTS IN FORCE
- 0 US APPLICATIONS PENDING
- May 27, 2003 most recent publication
Details
- 11 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 1,311 Total Citation Count
- Jun 23, 1986 Earliest Filing
- 30 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
- No Recent Publications to Display
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
6555328 Screening methods for altering circadian rhythms and for human casein kinase I .delta. and/or .epsilon. phosphorylation of human clock proteins, period 1, -2 and -3Jun 07, 00Apr 29, 03[C12Q]
RE37650 Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinaseFeb 02, 00Apr 09, 02[A61K]
6034093 Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compoundsAug 06, 98Mar 07, 00[A61K, C07D]
5958918 Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-?(aminominomethyl)phenylalkyl!-azaheterocyclylamide compoundsNov 21, 97Sep 28, 99[A61K, C07D]
5912365 Derivatives of 2-azabicyclo?2.2.1! heptane, their preparation and their applicationAug 19, 97Jun 15, 99[C07D]
5731315 Substituted sulfonic acid n-?(aminoiminomethyl)phenylalkyl!-azaheterocyclamide compoundsDec 06, 96Mar 24, 98[A61K, C07D]
5714493 Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinaseJun 04, 96Feb 03, 98[A61K]
5710158 Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinaseApr 19, 94Jan 20, 98[A61K, C07D]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2002/0146,829 Neutral and anionic colloidal particles for gene deliveryAbandonedNov 29, 01Oct 10, 02[A61K, C12N]
2002/0013,310 Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compoundsAbandonedJul 30, 01Jan 31, 02[A61K, C07D]
6281227 Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compoundsExpiredDec 02, 99Aug 28, 01[A61K, C07D]
6274705 Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptidesExpiredAug 21, 98Aug 14, 01[C07K]
6235909 Preparation of is-[1A,2B,3B,4A(S*)]-4-[7-[[1-(3-chloro-2-Thienyl)methyl]amino]-3H-imidazo [4,5-B]pyridin-3-YL]-N-ethyl-2,3-dihydroxycyclopentanecarboxamideExpiredJul 28, 00May 22, 01[C07D]
6159978 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56.sup.lck tyrosine kinasesExpiredNov 24, 98Dec 12, 00[A61K, C07D]
6153588 Stable non-hygroscopic crystalline form of N-[N-[N-4-(piperidin-4-yl)butanoyl)-N-ethylglycyl] aspartyl]-L-.beta.-cyclohexyl alanine amideExpiredFeb 18, 99Nov 28, 00[A61K, C07K]
6153597 Pharmaceutical composition useful for nucleic acid transfection, and use thereofExpiredMar 27, 98Nov 28, 00[A61K]
6143508 Device and process for cell capture and recoveryExpiredJun 07, 95Nov 07, 00[A61K, C12N, C07K]
6143894 Preparation of [1S-[1A,2B,3B,4A(S*)]]-4-[7-[[1-(3-chloro-2-thienyl)methyl propyl]amino] -3H-imidazo[4,5-B]pyridin-3-yl]-N-ethyl-2,3-dihydroxycyclopentanecarboxa mideExpiredJan 19, 99Nov 07, 00[C07D]
6127550 Stereospecific preparation of chiral 1-aryl-and 1-heteroaryl-2-substituted ethyl-2-aminesExpiredMar 11, 99Oct 03, 00[C07D, C07C]
5736554 Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic propertiesExpiredMay 31, 95Apr 07, 98[A61K, C07D]
5652366 DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereofExpiredJun 07, 95Jul 29, 97[C07D]
5561134 Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic propertiesExpiredOct 03, 94Oct 01, 96[A61K, C07D]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.